Drug intelligence / Profile preview

haloperidol + promethazine

Development stage
Phase 4
Lead developer
Johnson & Johnson
Modality
Small Molecules
Administration
Intramuscular (most Common For Rapid Tranquillisation)[1][2][4], Oral (less Common; Not Standard For This Indication)
01

Overview

Haloperidol + promethazine is a fixed-dose combination of two drugs used primarily for the rapid tranquillisation of acutely agitated or violent patients, especially in psychiatric emergency settings. Haloperidol is a first-generation (typical) antipsychotic that acts mainly as a dopamine D2 receptor antagonist, reducing psychotic symptoms and agitation[6]. Promethazine is a first-generation antihistamine with sedative properties, acting as an antagonist at histamine H1 receptors and also possessing anticholinergic effects[10]. The combination enhances sedation, reduces the risk of extrapyramidal side effects (such as acute dystonia), and provides more rapid calming than haloperidol alone or some benzodiazepines[1][2][4][5]. This regimen is widely used in countries such as India and Brazil for behavioural emergencies. The addition of promethazine to haloperidol improves safety by lowering the incidence of serious adverse events compared to haloperidol monotherapy[2][5].

02

Targets

DRD2 (Dopamine D2 Receptor)HRH1 (Histamine H1 Receptor)mAChR (Muscarinic acetylcholine receptors)

Beyond the preview

Go deeper on haloperidol + promethazine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on haloperidol + promethazine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call